Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7CA | ISIN: US03836J2015 | Ticker-Symbol:
NASDAQ
02.10.25 | 21:56
1,490 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APREA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APREA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APREA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.09.Aprea Therapeutics, Inc. - 8-K, Current Report1
12.08.Aprea Therapeutics GAAP EPS of -$0.53 1
12.08.Aprea Therapeutics, Inc. - 10-Q, Quarterly Report1
12.08.Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update157Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor...
► Artikel lesen
12.08.Aprea Therapeutics, Inc. - 8-K, Current Report-
APREA THERAPEUTICS Aktie jetzt für 0€ handeln
25.06.Aprea Therapeutics: Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with ...121Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti-PD-1 therapy Initial Phase 1 clinical...
► Artikel lesen
09.06.Aprea Therapeutics, Inc. - 8-K, Current Report3
14.05.Aprea Therapeutics GAAP EPS of -$0.661
14.05.Aprea Therapeutics, Inc. - 10-Q, Quarterly Report1
14.05.Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update128ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial ...
► Artikel lesen
14.05.Aprea Therapeutics, Inc. - 8-K, Current Report-
25.03.Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update194ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119...
► Artikel lesen
11.03.Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)183DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments...
► Artikel lesen
11.12.24Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward261Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1